155 related articles for article (PubMed ID: 29344282)
1. Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.
Tajima JY; Futamura M; Gaowa S; Mori R; Tanahashi T; Tanaka Y; Matsuhashi N; Takahashi T; Yamaguchi K; Miyazaki T; Yoshida K
J Cancer; 2018; 9(2):358-366. PubMed ID: 29344282
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
Kanematsu M; Futamura M; Takata M; Gaowa S; Yamada A; Morimitsu K; Morikawa A; Mori R; Hara H; Yoshida K
Cancer Med; 2015 Sep; 4(9):1344-55. PubMed ID: 26077887
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein non-metastatic melanoma B interacts with epidermal growth factor receptor to regulate neural stem cell survival and differentiation.
Yang H; Jin G; Chen S; Luo J; Xu W
Open Med (Wars); 2023; 18(1):20230639. PubMed ID: 36820063
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation.
Wang C; Okita Y; Zheng L; Shinkai Y; Manevich L; Chin JM; Kimura T; Suzuki H; Kumagai Y; Kato M
Cancer Sci; 2021 Oct; 112(10):4187-4197. PubMed ID: 34327762
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.
Taya M; Hammes SR
Steroids; 2018 May; 133():102-107. PubMed ID: 29097143
[TBL] [Abstract][Full Text] [Related]
6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
7. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
8. Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na+/K+-ATPase.
Ono Y; Tsuruma K; Takata M; Shimazawa M; Hara H
Sci Rep; 2016 Mar; 6():23241. PubMed ID: 26988030
[TBL] [Abstract][Full Text] [Related]
9. The laminin-derived peptide C16 regulates GPNMB expression and function in breast cancer.
Smuczek B; Santos ES; Siqueira AS; Pinheiro JJV; Freitas VM; Jaeger RG
Exp Cell Res; 2017 Sep; 358(2):323-334. PubMed ID: 28689015
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer.
Ruan WM; Li YL; Nie G; Zhou WX; Zou XM
Int J Clin Exp Med; 2014; 7(12):4857-66. PubMed ID: 25663982
[TBL] [Abstract][Full Text] [Related]
12. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
Takegawa N; Yonesaka K
Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury.
Nakano Y; Suzuki Y; Takagi T; Kitashoji A; Ono Y; Tsuruma K; Yoshimura S; Shimazawa M; Iwama T; Hara H
Neuroscience; 2014 Sep; 277():123-31. PubMed ID: 25010402
[TBL] [Abstract][Full Text] [Related]
14. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.
Ciardiello F; Tortora G
Clin Cancer Res; 1998 Apr; 4(4):821-8. PubMed ID: 9563874
[TBL] [Abstract][Full Text] [Related]
15. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE
Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642
[TBL] [Abstract][Full Text] [Related]
16. Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy.
Qin C; Liu Z; Yuan Y; Zhang X; Li H; Zhang C; Xu T; Wang X
Mol Med Rep; 2014 Mar; 9(3):851-6. PubMed ID: 24425288
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
